Related Experiment Video
Updated: Nov 9, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
BRD4: An emerging prospective therapeutic target in glioma
1Department of Basic Medicine and Biomedical Engineering, School of Medicine, Foshan University, Foshan 528000, Guangdong Province, China.
Abstract:
Despite advances in treatment, the prognosis for glioma patients remains poor. Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extraterminal (BET) protein family, plays an important role in controlling oncogene expression and genome stability. In recent years, numerous BRD4 inhibitors have entered clinical trials and achieved exciting results in tumor treatment. Recent clinical studies have shown that BRD4 expression in glioma is significantly higher than in the adjacent normal brain tissue. BRD4 inhibitors effectively penetrate the blood-brain barrier and target glioma tumor tissues but have little effect on normal brain tissues. Thus, BRD4 is a target for the treatment of glioma. In this study, we discuss the progress in the use of BRD4 inhibitors for glioma treatment, their mechanism of action, and their broad potential clinical application.
Insights
Bromodomain-containing protein 4 (BRD4) inhibitors show promise for treating glioma, a type of brain cancer. These inhibitors target high BRD4 expression in tumors, crossing the blood-brain barrier with minimal impact on healthy tissues.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- Glioma prognosis remains poor despite treatment advances.
- Bromodomain-containing protein 4 (BRD4) is crucial for oncogene expression and genome stability.
- Elevated BRD4 expression is observed in glioma compared to normal brain tissue.
Purpose of the Study:
- To review the progress of BRD4 inhibitors in glioma treatment.
- To elucidate the mechanism of action of BRD4 inhibitors.
- To discuss the clinical potential of BRD4 inhibitors for glioma.
Main Methods:
- Literature review of BRD4 inhibitors in preclinical and clinical studies.
- Analysis of BRD4 expression patterns in glioma.
- Assessment of BRD4 inhibitor pharmacokinetics, including blood-brain barrier penetration.
Main Results:
- BRD4 inhibitors have demonstrated efficacy in preclinical glioma models.
- BRD4 inhibitors effectively target glioma cells and penetrate the blood-brain barrier.
- BRD4 inhibitors exhibit a favorable safety profile with limited effects on normal brain tissues.
Conclusions:
- BRD4 is a validated therapeutic target for glioma treatment.
- BRD4 inhibitors represent a promising new class of drugs for managing glioma.
- Further clinical investigation of BRD4 inhibitors is warranted for glioma patients.
More Related Videos
Related Concept Videos
00:49The Blood-brain Barrier
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...